Our immunohistochemical analysis further suggests that the ALKBH3 expression profile of tumours may be a predictive factor for tumour recurrence of adenocarcinoma, in particular, and may also join EGFR mutational analysis as a marker for sensitivity to chemoradiation. The gene discussed is EGFR; the disease is adenocarcinoma.